An early-stage biotech company focused on expedient development of a first-in-class treatment for NASH, TB-019.  Our experienced team, along with our partners, are advancing TB-019 through IND enabling studies with plans for an initial clinical trial in early 2023.


TamuroBio, Inc is an early-stage biotech company with a mission to transform the lives of patients suffering from NASH.  The technology stems from approximately two decades of research on polyamines and obesity conducted in the laboratory of Dr. Salim Merali at the Temple University School of Pharmacy and two decades of medicinal chemistry experience of Dr. Wayne Childers at the Moulder Center for Drug Discovery in the School of Pharmacy and Wyeth Pharmaceuticals.

The focus of TamuroBio has been on pre-clinical candidate, TB-019, which is designed to sequester the lipotoxic product, 4-hydroxynonenal (4-HNE), and treat non-alcoholic steatohepatitis (NASH). 

 TB-019 offers a novel mechanism of action that has demonstrated both prevention and treatment of NASH in preclinical models. Through further research and development of its technology, the TamuroBio team remains both well-poised and committed to achieving the goal of providing a meaningful therapy to NASH patients.


Maxine Gowen, PhD, MBA – Director & Senior Advisor

Prior to TamuroBio, Dr. Gowen was the founding CEO of Trevena and served as its President and Chief Executive Officer from 2007 until October 2018. Prior to joining Trevena, Dr. Gowen held a variety of leadership roles at GlaxoSmithKline (GSK) over a period of fifteen years. As Senior Vice President for the Center of Excellence for External Drug Discovery (CEEDD), she developed an innovative new approach to externalizing drug discovery in the pharmaceutical industry. Dr. Gowen was previously President and Managing Partner at SR One, the venture capital subsidiary of GSK, where she led its investments in and served on the board of directors of numerous companies. Until 2002 Dr. Gowen was Vice President, Drug Discovery, Musculoskeletal Diseases at GSK, responsible for drug discovery and early development for osteoporosis, arthritis and metastatic bone disease. Dr. Gowen held a tenured academic position in the School of Pharmacology, University of Bath, UK from 1989 until 1992. She has authored more than 100 refereed scientific publications. She serves on the boards of Trevena Inc, (TRVN), Akebia Therapeutics, Inc. (AKBA), Idera Pharmaceuticals, Inc. (IDRA), Passage Bio (PASG), and Aclaris Therapeutics (ACRS), all public biopharmaceutical companies. She also serves on the board and executive committee of the Pennsylvania biotechnology innovation association, Life Sciences PA. Dr. Gowen served on the board of the national biotechnology industry association, BIO, from 2008 to 2018. Dr. Gowen graduated with a B.Sc. in biochemistry from the University of Bristol, UK, a Ph.D. in cell biology from the University of Sheffield, UK, and an MBA from the Wharton School of the University of Pennsylvania. She also was awarded a Doctor of Science by the University of Bath, UK in 2018.

Salim Merali, PhD – Founder, Professor, Temple University

Dr. Merali is currently an Associate Dean of Research and Laura H. Carnell Professor of Pharmacy at the Temple School of Pharmacy. Dr. Merali also is a Director of the Proteomics Facility at Temple University. He has vast experience in identifying novel molecular transducers as biomarkers and therapeutic targets. TamuroBio, Inc. lead candidate, TB-019, was developed over 12 years in his laboratory. Dr. Merali has raised over $15M in grant funding, mostly from NIH, to support the efforts of understanding the pathophysiology of diseases to identify drug targets. His focus on human studies resulted in the seminal publication in Science Translational Medicine that has been characterized as a molecular basis for the cause of insulin resistance. Dr. Salim Merali received his BS, MS, and PhD degrees in Biochemistry from The City University of New York. While completing his doctoral program, Dr. Merali joined New York University (1992-2005) to work on drug development on opportunistic fungal pathogens in AIDS (Pneumocystis). He also developed state of the art technology in Proteomics and Metabolomics. He joined Temple University School of Medicine (2005-2013) as Associate Professor of Biochemistry, The Fels Institute of Cancer Research and Molecular Biology, and Director of the Proteomics Core Facility. Dr. Merali joined The School of Pharmacy in November 2013.

Mahmoud Ghazzi, MD, PhD – Chief Medical Officer

Dr. Mahmoud Ghazzi is an experienced Physician Scientist with extensive leadership experience across Phase 1-4 of drug development at Warner-Lambert/Pfizer, GSK, and Daiichi Sankyo. With over 25 years of experience, Dr. Ghazzi has held several executive leadership roles that cover the spectrum of Drug Development including President, Global Development Head, Chief Medical Advisor, Medicine Development Center Head, and Therapeutic Area Head. Prior to consulting, his most recent role was President, Daiichi-Sankyo Pharmaceutical Development, and Global Development Head, Daiichi-Sankyo Research & Development. Dr. Ghazzi earned his MD from the School of Medicine at Damascus University in Syria and a MPH degree, as well as a Ph.D. in Bioengineering, from the University of Michigan.

Maha Ghazzi, PharmD – Program Lead

Dr. Maha Ghazzi has over 20 years of experience in the pharmaceutical industry. Prior to consulting, she has worked at Pfizer, most recently as Executive Director/Development Team Leader. In this role, she was responsible for leading late-stage development teams for several candidates in thrombosis (apixaban) and atherosclerosis (Biologics: HDL infusions). Dr. Ghazzi also provided cross functional leadership to develop an integrated strategy, communicate with senior management for endorsement, and ensure timely implementation of agreed plans. She worked closely with opinion leaders and experts in the field in order to ensure that the clinical development plan was optimized to meet regulatory and commercial needs. Additionally, she interacted with regulatory agencies (FDA, CHMP, and PMDA) for alignment on clinical and non-clinical development plans. Dr. Maha Ghazzi earned her Doctor of Pharmacy at the University of Michigan College of Pharmacy in Ann Arbor, Michigan.